CHING-HUNG LINTang C.-H.2021-07-282021-07-2820180167-6806https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052535365&doi=10.1007%2fs10549-018-4872-1&partnerID=40&md5=5ffa014c6f435222232b3c2dbe6a78aehttps://scholars.lib.ntu.edu.tw/handle/123456789/575316[SDGs]SDG3anthracycline; glucocorticoid; breast cancer; cancer chemotherapy; cancer classification; cancer survival; cancer therapy; dose response; drug use; human; Letter; overall survival; physician; priority journal; progression free survival; prospective study; selection biasRebuttal comments on “Glucocorticoids in breast cancer treatment: Real benefit or selection bias?”letter10.1007/s10549-018-4872-1300735492-s2.0-85052535365